The partners will work together on a US commercialization strategy for Genetic Technologies' line of existing and future polygenic risk tests.
The firm's lab subsidiary Phenogen will provide genotyping to study the impact on women's decisions to undergo prophylactic surgery.
The planned joint venture with Beijing Zishan Health Consultancy is aimed at bringing Genetic Technologies' genomic tests to the Chinese market.
The company intends to use the proceeds for, among other things, investigating the use of blockchain technology in medicine and biotechnology.
The deal comes a little more than month after the companies agreed to form a joint venture that will develop a blockchain-based healthcare service platform.
A new company will be established to develop a service platform using blockchain technology for medical services and personalized health management.
The partners are aiming to broaden the applicability of Genetic Technologies' BrevaGenplus breast cancer risk assessment test.
The partners aim to develop and access a blockchain-based genomic data management platform for cancer diagnostic development.
Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.
Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.
St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.
St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.
In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.